Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Leading healthcare information technology solutions provider Cerner Corporation (CERN - Analyst Report) recently reported that its board of directors has decided to implement a 2 for 1 stock split through a 100% stock dividend. The decision took take place at a meeting of the board on May 24, 2013.

Cerner had about 172.3 million common stock shares on May 24, 2013. The split will increase its share count to about 344.6 million shares. Every shareholder as of June 17, 2013 will receive an extra share for each share held as of this date. The date for distribution of the new shares will be around June 28, 2013.

Cerner remains the trend setter among pure-play, publicly traded healthcare information technology vendors. The company is diversified not only on a global basis but serves both hospitals and ambulatory outfits. Its integrated solutions have captured market share. While fresh opportunities are shrinking, the replacement market is growing.

We believe long-term investors may consider Cerner, which serves a sizeable installed inpatient base that requires composite clinically-oriented applications complying with “meaningful use” requirements, reimbursement problems and complicated coding issues. The company has long-standing, integrated and seamless solutions for both inpatient and ambulatory settings.

On the negative side, the federal Stimulus program will gradually have to wind down. Cerner faces stiff competition from established HCIT players, such as Athenahealth, Inc. (ATHN - Analyst Report).

Cerner offerings are used by about 10,000 health care entities worldwide. This count includes over 45,000 doctors, 2,700 hospitals and 4,150 physician practices.

We currently have a Zacks Rank #3 (Hold) on Cerner. However, we are more positive about other stocks such as Merge Healthcare Incorporated (MRGE - Analyst Report) and Omnicell Inc. (OMCL - Analyst Report) both of which carry a Zacks Rank #2 (Buy) and are expected to do well. 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%